Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5344278 | 0.80 | MTNR1A (0.72) | MTNR1AMTNR1BTRPV1 | |
| SCHEMBL5346519 | 0.79 | MTNR1A (0.70) | MTNR1AMTNR1BTRPV1MAPT | |
| SCHEMBL5334595 | 0.79 | MTNR1A (0.70) | MTNR1AMTNR1BTRPV1 | |
| SCHEMBL5346165 | 0.79 | MTNR1A (0.70) | MTNR1AMTNR1BTRPV1 | |
| SCHEMBL6076652 | 0.79 | MTNR1A (0.70) | MTNR1AMTNR1BTRPV1 | |
| SCHEMBL19658437 | 0.78 | MTNR1A (0.65) | MTNR1AMTNR1B | |
| SCHEMBL5261920 | 0.77 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL7198777 | 0.76 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP2C19NPSR1 | |
| SCHEMBL7822666 | 0.74 | MTNR1A (0.77) | MTNR1AMTNR1BTRPV1 | |
| SCHEMBL5336254 | 0.74 | MTNR1A (0.70) | MTNR1AMTNR1BCYP1A2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1139584-C | Heterocyclic compounds, method for preparing and medicine compositions containing same | ɪά��ʵ���� | 2004-02-25 | — | — | CN | disclosed |
| US-6602903-B2 | Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. | LES LABORATORIES SERVIER (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020052400-A1 | Substituted heterocyclic compounds | ADIR ET COMPAGNIE | 2002-05-02 | — | — | US | disclosed |
| US-6313160-B1 | FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052400-A1 | Substituted heterocyclic compounds | MTNR1A, MTNR1B, CBR1 | MTNR1A 1/4885MTNR1B 2/4885CYP1A2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.